Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group. Ziemssen T, et al. Among authors: lang m. Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 30882022 Free PMC article.
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group. Ziemssen T, et al. Among authors: lang s, lang m. J Neurol. 2022 Jun;269(6):3276-3285. doi: 10.1007/s00415-021-10931-w. Epub 2022 Jan 4. J Neurol. 2022. PMID: 34982201 Free PMC article.
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W. Limmroth V, et al. Among authors: lang m. BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7. BMC Neurol. 2017. PMID: 28100182 Free PMC article.
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group. Ziemssen T, et al. Among authors: lang m. Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y. Neurotherapeutics. 2018. PMID: 29274026 Free PMC article.
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG. Pfeuffer S, et al. Among authors: lang m. J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16. J Neurol. 2019. PMID: 30446966
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].
Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H. Klotz L, et al. Among authors: lang m. Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Nervenarzt. 2016. PMID: 26927677 Free article. Review. German.
2,256 results